Covance Business Unit Names New Leaders

Following the recent announcement that Dr. Paul Kirchgraber would assume the role of CEO of Covance, two key leadership appointments will also become effective November 1.

Jon DiVincenzo, Senior VP, is the incoming head of Clinical Trials Testing Solutions, with oversight of Covance Central Laboratory Services (CLS), Chemistry Solutions (including BioAnalytical and Chemistry Manufacturing & Controls), and Global Specimen Solutions. Patrick Hastings, VP, has been named incoming head of the CLS organization.

DiVincenzo joined Covance in 2017, bringing more than 30 years’ experience in life science and analytical instrumentation, focused on driving international growth, executing strategic objectives and building high-performance teams, particularly in biotechnology, pharmaceutical and clinical institutions. Most recently, served as SVP and head of Covance’s Chemistry Solutions organization. Prior to joining Covance, DiVincenzo was CEO of a Boston-based Contract Manufacturing Organization (CMO), supplying the DNA sequencing market. He is a graduate of Northeastern University in Boston where he earned a Bachelor’s Degree in Mechanical Engineering and holds certificates in Product Management and Marketing from the University of Wisconsin in Madison.

Hastings joined Covance in 2016. Most recently, he served as VP, Global Operations and Client Delivery for CLS, providing him with substantial insight about both the business and our exceptional people. Prior to Covance, Hastings led the global Clinical Trials production and supply chain operations for Eli Lilly & Company supporting more than 13,000 clinical sites with an extensive internal and external manufacturing network. In addition, Hastings served as Chief Operating Officer for a medical device firm, where he successfully led the launch of more than 25 innovative products supporting the oncology laboratory testing industry, and drove several transformational initiatives to significantly improve revenue and margin. He earned his Master’s Degree in Engineering from Rutgers University, a Bachelor of Science degree from Michigan State University, and Executive Management certifications from the Kellogg School of Management at Northwestern University and the University of Notre Dame.

“I have worked with Jon and Patrick personally for several years and know they will continue to strengthen the Covance culture and way of working,” said Kirchgraber. “Moreover, I’m confident that Jon and Patrick are ready for their new opportunities ahead based on their previous track record of success.”

About LabCorp

Covance is the drug development business of LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11 billion in 2018. To learn more about LabCorp, visit www.LabCorp.com, and to learn more about Covance Drug Development, visit www.Covance.com